ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap | Zendy

HansJoachim Anders | Zendy; Brad H. Rovin | Zendy; David Jayne | Zendy; Paul Brunetta | Zendy; Rosanna Coppo | Zendy; Anne Davidson | Zendy; Satish Kumar Devarapu | Zendy; Dick de Zeeuw | Zendy; Jeremy S. Duffield | Zendy; Dirk Eulberg | Zendy; Alberto Fierro | Zendy; Jürgen Floege | Zendy; Steffen Frese | Zendy; Loı̈c Guillevin | Zendy; Stephen R. Holdsworth | Zendy; Jeremy Hughes | Zendy; Ralph Kettritz | Zendy; Malte A. Kluger | Zendy; Christian F. Krebs | Zendy; Larissa Lapteva | Zendy; Adeera Levin | Zendy; Jinhua Li | Zendy; Liz Lightstone | Zendy; Matthias Mack | Zendy; Ladan Mansouri | Zendy; Stephen P. McAdoo | Zendy; Eoin McKinney | Zendy; Ulf Panzer | Zendy; Samir M. Parikh | Zendy; Charles D. Pusey | Zendy; Chaim Putterman | Zendy; Ton J. Rabelink | Zendy; Andreas Radbruch | Zendy; Andrew J. Rees | Zendy; Mary M. Reilly | Zendy; Marlies E. J. Reinders | Zendy; Giuseppe Remuzzi | Zendy; Piero Ruggenenti | Zendy; Steven H. Sacks | Zendy; Thomas J. Schall | Zendy; Catherine Meyer-Schwesinger | Zendy; Kumar Sharma | Zendy; Yusuke Suzuki | Zendy; Nicola M. Tomas | Zendy; MingHui Zhao | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap

Author(s) -

HansJoachim Anders,

Brad H. Rovin,

David Jayne,

Paul Brunetta,

Rosanna Coppo,

Anne Davidson,

Satish Kumar Devarapu,

Dick de Zeeuw,

Jeremy S. Duffield,

Dirk Eulberg,

Alberto Fierro,

Jürgen Floege,

Steffen Frese,

Loı̈c Guillevin,

Stephen R. Holdsworth,

Jeremy Hughes,

Ralph Kettritz,

Malte A. Kluger,

Christian F. Krebs,

Larissa Lapteva,

Adeera Levin,

Jinhua Li,

Liz Lightstone,

Matthias Mack,

Ladan Mansouri,

Stephen P. McAdoo,

Eoin McKinney,

Ulf Panzer,

Samir M. Parikh,

Charles D. Pusey,

Chaim Putterman,

Ton J. Rabelink,

Andreas Radbruch,

Andrew J. Rees,

Mary M. Reilly,

Marlies E. J. Reinders,

Giuseppe Remuzzi,

Piero Ruggenenti,

Steven H. Sacks,

Thomas J. Schall,

Catherine Meyer-Schwesinger,

Kumar Sharma,

Yusuke Suzuki,

Nicola M. Tomas,

MingHui Zhao

Publication year - 2016

Publication title -

kidney international reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.225

H-Index - 22

ISSN - 2468-0249

DOI - 10.1016/j.ekir.2016.06.009

Subject(s) - translational research , medicine , nexus (standard) , translational medicine , translational science , nephrology , drug development , disease , kidney disease , bioinformatics , drug , pharmacology , pathology , biology , engineering , embedded system

To date, the treatment of immune-mediated kidney diseases has only marginally benefited from highly specific biological drugs that have demonstrated remarkable effects in many other diseases. What accounts for this disparity? In April 2016, the International Society of Nephrology held a Nexus meeting on Translational Immunology in Nephrology in Berlin, Germany, to identify and discuss hurdles that block the translational flow of target identification, and preclinical and clinical target validation in the domain of immune-mediated kidney disease. A broad panel of experts including basic scientists, translational researchers, clinical trialists, pharmaceutical industry drug developers, and representatives of the American and European regulatory authorities made recommendations on how to overcome such hurdles at all levels of the translational research process. The results of these discussions are presented here, which may serve as a roadmap for how to optimize the process of developing more innovative and effective drugs for patients with immune-mediated kidney diseases

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research